{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:17:53Z","timestamp":1790713073245,"version":"4.1.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl. 5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2314,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Recent studies suggest that long-term suppression of viral replication is critical to reducing the complications of chronic hepatitis B virus (HBV) infection. Monitoring for continued virological response during and after treatment is essential because current treatment options have limited success in achieving durable endpoints, and antiviral resistance may emerge during long-term therapy. Methods of monitoring treatment response include tests for serum aminotransferase levels, HBV DNA level, hepatitis B e antigen (HBeAg) and antibody (anti-HBe), hepatitis B surface antigen (HBsAg) or antibody (anti-HBs), and liver histology. Virological suppression and loss of HBeAg or HBsAg with or without seroconversion play a prominent role in decision-making regarding the success and duration of antiviral therapy. Guidelines recommend that testing for serum markers be repeated every 12-24 weeks during antiviral therapy and every 6-12 months afterward. Recent data also suggest that serum HBV DNA levels should be assessed at weeks 12 and 24 of therapy, because early viral response may predict the likelihood of sustained response and antiviral resistance. The use of serum HBV DNA levels for this purpose requires an assay with a wide range of quantification, such as real-time polymerase chain reaction assays, which have a 7-8 log<jats:sub>10<\/jats:sub> dynamic range. Newer, investigational methods for monitoring treatment response include quantitative measurement of HBsAg, HBeAg, and intrahepatic covalently closed circular DNA. <jats:italic toggle=\"yes\">Conclusions:<\/jats:italic> Better methods for defining durable treatment endpoints are needed. Other areas requiring further research include the optimal treatment duration and the establishment of the optimal use of early viral kinetics for decision-making during antiviral therapy. (Hepatology 2009;49:S166\u2013S173.)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.22899","type":"journal-article","created":{"date-parts":[[2010,7,5]],"date-time":"2010-07-05T12:30:37Z","timestamp":1278333037000},"page":"S166-S173","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":57,"title":["Monitoring during and after antiviral therapy for hepatitis B #"],"prefix":"10.1097","volume":"49","author":[{"given":"Karin L.","family":"Andersson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20241201","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"R2-20-20241201","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"R3-20-20241201","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cgh.2006.03.017","article-title":"Chronic hepatitis B: current testing strategies.","volume":"4","author":"Gish","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R4-20-20241201","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.gastro.2007.11.036","article-title":"Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.","volume":"134","author":"Pawlotsky","year":"2008","journal-title":"Gastroenterology"},{"key":"R5-20-20241201","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.cgh.2007.05.004","article-title":"Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.","volume":"5","author":"Keeffe","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R6-20-20241201","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease.","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"R7-20-20241201","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.21627","article-title":"Management of hepatitis B: summary of a clinical research workshop.","volume":"45","author":"Hoofnagle","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R8-20-20241201","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/gast.2001.24839","article-title":"Management of hepatitis B: 2000-summary of a workshop.","volume":"120","author":"Lok","year":"2001","journal-title":"Gastroenterology"},{"key":"R9-20-20241201","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B.","volume":"45","author":"Lok","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R10-20-20241201","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A oneyear trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.","volume":"339","author":"Lai","year":"1998","journal-title":"N Engl J Med"},{"key":"R11-20-20241201","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis B virusinfected asymptomatic patients with persistently normal ALT.","volume":"134","author":"Kumar","year":"2008","journal-title":"Gastroenterology"},{"key":"R12-20-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum alanine aminotransferase levels.","volume":"137","author":"Prati","year":"2002","journal-title":"Ann Intern Med"},{"key":"R13-20-20241201","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cgh.2008.02.037","article-title":"Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels.","volume":"6","author":"Tsang","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R14-20-20241201","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1053\/jhep.2003.50208","article-title":"Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature.","volume":"37","author":"MommejaMarin","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R15-20-20241201","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cgh.2008.03.026","article-title":"Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment.","volume":"6","author":"Chan","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"R16-20-20241201","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0168-8278(03)00136-3","article-title":"Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics.","volume":"39","author":"Pawlotsky","year":"2003","journal-title":"J Hepatol"},{"key":"R17-20-20241201","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1128\/JCM.01180-07","article-title":"Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections.","volume":"45","author":"Thibault","year":"2007","journal-title":"J Clin Microbiol"},{"key":"R18-20-20241201","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1128\/JCM.01248-07","article-title":"Performance of the Cobas AmpliPrepCobas TaqMan realtime PCR assay for hepatitis B virus DNA quantification.","volume":"46","author":"Chevaliez","year":"2008","journal-title":"J Clin Microbiol"},{"key":"R19-20-20241201","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/hep.21939","article-title":"Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5year ideal response.","volume":"46","author":"Yuen","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R20-20-20241201","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1086\/315147","article-title":"Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine.","volume":"180","author":"Gauthier","year":"1999","journal-title":"J Infect Dis"},{"key":"R21-20-20241201","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/gast.2003.50013","article-title":"Histological outcome during longterm lamivudine therapy.","volume":"124","author":"Dienstag","year":"2003","journal-title":"Gastroenterology"},{"key":"R22-20-20241201","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","article-title":"Longterm therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B.","volume":"352","author":"Hadziyannis","year":"2005","journal-title":"N Engl J Med"},{"key":"R23-20-20241201","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/MCG.0b013e31804bbdff","article-title":"Changes in liver histology as a surrogate end point of antiviral therapy for chronic HBV can predict progression to liver complications.","volume":"42","author":"Hui","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"R24-20-20241201","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1053\/jhep.2003.50458","article-title":"Determinants for sustained HBeAg response to lamivudine therapy.","volume":"38","author":"Chien","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R25-20-20241201","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJM199605303342202","article-title":"Longterm followup of HBeAgpositive patients treated with interferon alfa for chronic hepatitis B.","volume":"334","author":"Niederau","year":"1996","journal-title":"N Engl J Med"},{"key":"R26-20-20241201","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after longterm followup of HBeAgpositive patients treated with peginterferon alpha2b.","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"key":"R27-20-20241201","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/gast.1997.v113.pm9352870","article-title":"Longterm followup of patients with chronic hepatitis B treated with interferon alfa.","volume":"113","author":"Lau","year":"1997","journal-title":"Gastroenterology"},{"key":"R28-20-20241201","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1572-0241.1998.00272.x","article-title":"Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP).","volume":"93","author":"Fattovich","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"R29-20-20241201","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Longterm therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years.","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"R30-20-20241201","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B.","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"R31-20-20241201","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1086\/523585","article-title":"Rapid virologic response: a new milestone in the management of chronic hepatitis C.","volume":"46","author":"Poordad","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R32-20-20241201","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1440-1746.2005.04035.x","article-title":"Early virological response predicts outcome during extended lamivudine retreatment in patients with chronic hepatitis B who relapsed after initial HBeAg responses.","volume":"21","author":"Jang","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"R33-20-20241201","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/jhep.2001.27563","article-title":"Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.","volume":"34","author":"Yuen","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R34-20-20241201","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/jhep.2003.50117","article-title":"Durability of serologic response after lamivudine treatment of chronic hepatitis B.","volume":"37","author":"Dienstag","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R35-20-20241201","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/jhep.2000.16665","article-title":"Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.","volume":"32","author":"Song","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R36-20-20241201","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0168-8278(03)00394-5","article-title":"Longterm additional lamivudine therapy enhances durability of lamivudineinduced HBeAg loss: a prospective study.","volume":"39","author":"Ryu","year":"2003","journal-title":"J Hepatol"},{"key":"R37-20-20241201","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1136\/gut.52.12.1779","article-title":"Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for posttreatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion.","volume":"52","author":"Lee","year":"2003","journal-title":"Gut"},{"key":"R38-20-20241201","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S0168-8278(08)60105-1","article-title":"Virological and biochemical reponse in patients with HBeAgnegative chronic hepatitis B treated with peginterferon alfa2a (40kd) with or without lamivudine: results of 4year followup.","volume":"48","author":"Marcellin","year":"2008","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"RU39-20-20241201","first-page":"S3","article-title":"EASL International Consensus Conference on Hepatitis B. 1314 September, 2002 Geneva, Switzerland. Consensus statement (long version).","volume":"39","author":"de Franchis","year":"2003","journal-title":"J Hepatol"},{"key":"R40-20-20241201","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.cgh.2007.09.005","article-title":"Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.","volume":"5","author":"Chan","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R41-20-20241201","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.22065","article-title":"HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa2a for HBeAgpositive chronic hepatitis B.","volume":"47","author":"Fried","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R42-20-20241201","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels a guide to sustained response to peginterferon alfa2a in HBeAgnegative chronic hepatitis B.","volume":"49","author":"Brunetto","year":"2009","journal-title":"HEPATOLOGY"},{"key":"R44-20-20241201","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1053\/j.gastro.2005.03.009","article-title":"Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy.","volume":"128","author":"Sung","year":"2005","journal-title":"Gastroenterology"},{"key":"R45-20-20241201","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.","volume":"126","author":"WerleLapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"RU46-20-20241201","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2893.2008.01037.x","article-title":"Alanine aminotransferasebased algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B.","volume":"16","author":"Chan","year":"2009","journal-title":"J Viral Hepat"},{"key":"RU47-20-20241201","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1478-3231.2008.01802.x","article-title":"Noninvasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B.","volume":"29","author":"Marcellin","year":"2009","journal-title":"Liver Int"},{"key":"RU48-20-20241201","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3748\/wjg.v13.i4.525","article-title":"Sequential algorithms combining noninvasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.","volume":"13","author":"Sebastiani","year":"2007","journal-title":"World J Gastroenterol"},{"key":"RU49-20-20241201","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cgh.2007.06.012","article-title":"Assessment of hepatic fibrosis with magnetic resonance elastography.","volume":"5","author":"Yin","year":"2007","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22899","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200905001-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:10:37Z","timestamp":1733058637000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200905001-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":48,"journal-issue":{"issue":"Suppl. 5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22899","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}